ARCHIVES

AACR Statement on Precancers Plays Key Role in NCI Agenda

This article is from The Cancer Letter archive.

Vol. 29 No. 22 | May 30, 2003

Download PDF Visit The Full Archive

Related Articles

AstraZeneca To Pay $335M In Illegal Pricing Penalties.

June 27, 2003

Feinstein Reintroduces New National Cancer Act

June 13, 2003

ASCO Explores White, Minority Cancer Problem

July 13, 1990

Recombinant TSH Avoids Need To Stop Replacement Therapy

January 27, 2006

ASCO Backs Central IRB For Cancer Trials, Stiffens Conflict-of-Interest Policies

May 2, 2003

Prostatectomy Lowers Death Risk Compared to Watchful Waiting

April 29, 2011